SharesGrow 7-Criteria Score
All 7 criteria scored · valuation-related highlighted on this page
Propanc Biopharma, Inc. (PPCBD) .
Criteria proven by this page:
- VALUE (0/100, Fail) — the composite valuation score falls below the 60/100 threshold required to pass.
Overall SharesGrow Score: 25/100 with 0/7 criteria passed.
SharesGrow 7-Criteria Score
~
HEALTH
67/100
Debt-to-Equity & liquidity
→ Health
Valuation Snapshot — PPCBD
Valuation Multiples
P/E (TTM)0.0
Forward P/EN/A
PEG RatioN/A
Forward PEGN/A
P/B Ratio0.00
P/S Ratio0.00
EV/EBITDA0.0
Per Share Data
EPS (TTM)$-332.55
Book Value / Share$0.00
Revenue / Share$0.00
FCF / Share$0.00
Yields & Fair Value
Earnings YieldN/A
Dividend Yield0.00%
P/E Ratio & Earnings Yield
Earnings Per Share (EPS) History
| Year |
EPS (Diluted) |
Revenue |
Net Income |
Net Margin |
| 2016 |
$-0.24 |
$0.00 |
$-9.41M |
- |
| 2017 |
$-1,120,730,000.00 |
$0.00 |
$-7.87M |
- |
| 2018 |
$-178,749,000.00 |
$0.00 |
$-7.04M |
- |
| 2019 |
$-10,969,600.00 |
$0.00 |
$-5.76M |
- |
| 2020 |
$-192,449.00 |
$0.00 |
$-4.74M |
- |
| 2021 |
$-797.39 |
$0.00 |
$-2.03M |
- |
| 2022 |
$-1,119,480.00 |
$0.00 |
$-2.66M |
- |
| 2023 |
$-31,268.40 |
$0.00 |
$-2.66M |
- |
| 2024 |
$-1,420.95 |
$0.00 |
$-1.82M |
- |
| 2025 |
$-332.55 |
$0.00 |
$-58.92M |
- |
